Protara Therapeutics (TARA) Income from Continuing Operations (2013 - 2026)

Protara Therapeutics' Income from Continuing Operations history runs 14 years deep, the most recent figure standing at 17973000.0 for Q1 2026.

• In Q1 2026, Income from Continuing Operations fell 42.99% year-over-year to 17973000.0; the TTM figure through Mar 2026 stood at 65507000.0 (down 38.43% YoY), while the FY2025 annual figure was 59526000.0, down 29.89% from the prior year.
• Income from Continuing Operations was 17973000.0 for Q1 2026 at Protara Therapeutics, up from 18913000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 7691000.0 in Q3 2022 to a low of 38877000.0 in Q4 2022.
• Historically, Income from Continuing Operations has averaged 13525882.35 across 5 years, with a median of 11219000.0 in 2024.
• The sharpest annual moves came in 2022 and 2023: Income from Continuing Operations plunged 280.1% in 2022, then soared 73.71% in 2023.
• A 5-year view of Income from Continuing Operations shows it stood at 38877000.0 in 2022, then jumped by 73.71% to 10221000.0 in 2023, then sank by 36.98% to 14001000.0 in 2024, then sank by 35.08% to 18913000.0 in 2025, then climbed by 4.97% to 17973000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 17973000.0 (Q1 2026), 18913000.0 (Q4 2025), and 13258000.0 (Q3 2025), per Business Quant data.